The GTJA Investment Group has led a RMB300 million (US$45 million) series B round in Akeso Biopharma, a Chinese innovative biotechnology company.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!
Register NowAlready have an account or paid subscription? Log in
